Last updated on December 2018

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)


Brief description of study

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

Clinical Study Identifier: NCT03535194

Contact Investigators or Research Sites near you

Start Over

Tomasz Blicharski

Lubelskie Centrum Diagnostyczne
Swidnik, Poland
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.